I recently read that the University of Washington Nicotinimide Riboside (NR) trial on heart failure patients will conclude in June. They could announce the results soon after or wait until a publication 6 to 12 months later. NR is a special derivative of vitamin B3 and has shown effectivenses against heart faiure in mice.
* a total of 30 participants with clinically stable, systolic heart failure (LVEF <40%) will undergo 2:1 randomization to NR 250mg PO twice daily or matching placebo
* NR (or matching placebo), will be increased weekly by 250mg/dose (500mg/day) to a final dose of 1000mg PO twice daily. Clinic visits with labs bi-weekly during dose escalation will assess HF symptoms and monitor labs [B-type natriuretic peptide (BNP), complete blood count (CBC), glycosylated hemoglobin, alanine aminotransferase (ALT), creatine kinase (CK), insulin/glucose, uric acid, electrolytes, blood urea nitrogen (BUN) and creatinine (Cr).
* Six-minute walk tests (6MWTs) at each visit (including Screening) to assess functional capacity B) Echocardiography at Baseline and Week 12 to assess LV systolic function (by real-time, 3D echocardiography) and diastolic function (by integrated Doppler and tissue Doppler imaging).
NR costs about $1.00 at 250 mg a day so $2.00 for 500 mg a day. A previous study unrelated to heart failure suggests that taking more than 500 mg a day boosts NAD+ levels only a bit more than 375 mg a day after the first month – around a 50% increase – whereas 250 mg a day provides a 40% sustained boost in NAD+. (125 mg of NR a day provides a 25% NAD boost.) That is for normal 60 to 80 year old non obese subjects. Trials have already demonstrated safety up to 1000mg a day. I've been taking 250mg for over a year.
The results from a University of Colorado NR trial with 30 subjects will be published soon and that includes before and after data for heart some heart effects as well.